SUPPLEMENTAL MATERIAL

Study population

Inclusion criteria


- Men or women 18-70 years of age
- HbA1C < 5.8%
- Able to provide written informed consent

Exclusion criteria

- Pregnancy or lactation
- Diagnosed with diabetes mellitus
- Weight change \geq 5 % within 3 months prior to admission to the study
- Has taken any weight loss medications within 3 months prior to admission to the study
- Immunocompromised status, including a debilitated state or malignancy
- Active liver, renal, thyroid diseases
- Frequent alcoholic consumption more than twice a week; with beer > 360 mL, alcohol > 45 mL, wine > 150 mL for female, or beer > 720 mL, whisky > 90 mL, wine > 300 mL for male each time
- Has gastrointestinal symptoms such as nausea, vomiting, loss of appetite, premature satiety, diarrhea, or chronic constipation
- Lack of ability or willingness to give informed consent
- Taken any medications than might cause weight loss or weight gain such as corticosteroid, antidepressant, antipsychotics, oral contraceptive pills < 8 weeks or change the dose of these medication with 8 week prior to admission
- Patients in cardiac Class II, III or IV.
- Patients who have had renal transplants or are currently receiving renal dialysis.
- Patients with the diagnosis of psychosis.
- Patients with known HIV infection.

- Patients with history of malignancy within the last one year with the exception of localized skin cancers.
- Patients with significant clinical signs or symptoms of liver disease, acute or chronic hepatitis, or aspartate transaminase (AST or SGOT) greater than three times the upper reference range limit.
- Patients with clinical signs or symptoms of drug or alcohol abuse.
- Patients with a life expectancy of less than 5 years.
- Patients with any cognitive impairment diagnosed previously
- Patients with a serum creatinine greater 1.5 mg/dl.
- Patients exhibiting serious non-compliance with prescribed diet or drug therapy.
- Patients who are currently participating or have participated in a medical, surgical, or pharmaceutical investigation in which an investigational new drug was dispensed to the patient within the last 30 days.
- Patients with a body mass index (B.M.I.) greater than 40 kg/m².
- Patients with a body mass index (B.M.I.) less than 20 kg/m².
- Any situation which precludes the patient from following and completing the protocol.
- Patients with known hemoglobinopathy or chronic anemia with hemoglobin <10gm/dL

Supplemental Figure 1. Comparison of plasma glucose levels among placebo and different D-allulose doses according to race (White vs. African American). Bars represent mean. Pvalues represent the treatment by race interaction and the total effect of race on plasma glucose at each time point. AA: African American; W: White.



rial which has been supplied by the author(s) BMJ Ope

Supplemental Figure 2. Comparison of insulin levels among placebo and different Dallulose doses according to race (White vs. African American). Bars represent mean. P-values represent the treatment by race interaction and the total effect of race on insulin at each time point. AA: African American; W: White.

